BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 22.00K USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $22.00K | (m) | (m) |
| 2026-03-31 | (m) | (m) | $15.00K | (m) | (m) |
| 2025-12-31 | (m) | (m) | $29.00K | (m) | (m) |
| 2025-09-30 | (m) | (m) | $5.00K | (m) | (m) |
| 2025-06-30 | (m) | (m) | $824.00K | (m) | (m) |
| 2025-03-31 | (m) | (m) | $1.64M | (m) | (m) |
| 2024-12-31 | (m) | (m) | $187.00K | (m) | (m) |
| 2024-09-30 | (m) | (m) | $168.00K | (m) | (m) |
| 2024-06-30 | (m) | (m) | $3.47M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $779.00K | (m) | (m) |
| 2023-12-31 | (m) | (m) | $1.30M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $1.22M | (m) | (m) |
| 2023-06-30 | (m) | (m) | $546.00K | (m) | (m) |
| 2023-03-31 | (m) | (m) | $2.02M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $772.00K | (m) | (m) |
| 2022-09-30 | (m) | (m) | $4.14M | (m) | (m) |
| 2022-06-30 | (m) | (m) | $9.01M | (m) | (m) |
| 2022-03-31 | (m) | (m) | $15.15M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $18.86M | (m) | (m) |
| 2021-09-30 | (m) | (m) | $25.70M | (m) | (m) |
| 2021-06-30 | (m) | (m) | $30.57M | (m) | (m) |
| 2021-03-31 | (m) | (m) | $35.93M | (m) | (m) |
| 2020-12-31 | (m) | (m) | $37.83M | (m) | (m) |
| 2020-09-30 | (m) | (m) | $24.77M | (m) | (m) |
| 2020-06-30 | (m) | (m) | $12.15M | (m) | (m) |
| 2020-03-31 | (m) | (m) | $12.47M | (m) | (m) |
| 2019-12-31 | (m) | (m) | $536.00K | (m) | (m) |
| 2019-09-30 | (m) | (m) | $2.10M | (m) | (m) |
| 2019-06-30 | (m) | (m) | $1.13M | (m) | (m) |
| 2019-03-31 | (m) | (m) | $3.24M | (m) | (m) |
| 2018-12-31 | (m) | (m) | $942.00K | (m) | (m) |
| 2018-09-30 | (m) | (m) | $697.00K | (m) | (m) |
| 2018-06-30 | (m) | (m) | $2.26M | (m) | (m) |
| 2018-03-31 | (m) | (m) | $3.25M | (m) | (m) |
| 2017-12-31 | (m) | (m) | $2.48M | (m) | (m) |
| 2017-09-30 | (m) | (m) | $2.46M | (m) | (m) |
| 2017-06-30 | (m) | (m) | $5.78M | (m) | (m) |
| 2017-03-31 | (m) | (m) | $604.00K | (m) | (m) |
| 2016-12-31 | (m) | (m) | $547.00K | (m) | (m) |
| 2016-09-30 | (m) | (m) | $955.00K | (m) | (m) |
| 2016-06-30 | (m) | (m) | $944.00K | (m) | (m) |
| 2016-03-31 | (m) | (m) | $2.21M | (m) | (m) |
| 2015-12-31 | (m) | (m) | $428.00K | (m) | (m) |
| 2015-09-30 | (m) | (m) | $710.00K | (m) | (m) |
| 2015-06-30 | (m) | (m) | $1.30M | (m) | (m) |
| 2015-03-31 | (m) | (m) | $3.49M | (m) | (m) |
| 2014-12-31 | (m) | (m) | $4.25M | (m) | (m) |
| 2014-09-30 | (m) | (m) | $8.97M | (m) | (m) |
| 2014-06-30 | (m) | (m) | $11.33M | (m) | (m) |
| 2014-03-31 | (m) | (m) | $3.03M | (m) | (m) |
| 2013-12-31 | (m) | (m) | $3.50M | (m) | (m) |
| 2013-09-30 | (m) | (m) | $329.00K | (m) | (m) |
| 2013-06-30 | (m) | (m) | $755.00K | (m) | (m) |
| 2013-03-31 | (m) | (m) | $1.87M | (m) | (m) |
| 2012-12-31 | (m) | (m) | $1.32M | (m) | (m) |
| 2012-09-30 | (m) | (m) | $4.78M | (m) | (m) |
| 2012-06-30 | (m) | (m) | $843.00K | (m) | (m) |
| 2012-03-31 | (m) | (m) | $1.15M | (m) | (m) |
| 2011-12-31 | (m) | (m) | $1.92M | (m) | (m) |
| 2011-09-30 | (m) | (m) | $2.39M | (m) | (m) |
| 2011-06-30 | (m) | (m) | $2.90M | (m) | (m) |
| 2011-03-31 | (m) | (m) | $3.66M | (m) | (m) |
| 2010-12-31 | (m) | (m) | $93.00K | (m) | (m) |
| 2010-09-30 | (m) | (m) | $749.00K | (m) | (m) |
| 2010-06-30 | (m) | (m) | $725.00K | (m) | (m) |
| 2009-12-31 | (m) | (m) | $1.00K | (m) | (m) |
| 2000-09-24 | (m) | (m) | $0.00 | (m) | (m) |
| 2000-09-22 | (m) | (m) | $0.00 | (m) | (m) |
| 2000-09-21 | (m) | (m) | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |